Smita Asare

3.5k citations
22 papers · 300 · h-index 7

Impact in

  • Transplantation top 10%
  • Oncology
    • Cancer Immunotherapy and Biomarkers
    • Cancer Cells and Metastasis
    • PARP inhibition in cancer therapy

Papers in

  • Oncology 13
    • Cancer Immunotherapy and Biomarkers 9
    • Cancer Treatment and Pharmacology 2
    • HER2/EGFR in Cancer Research 2
  • Cancer Research 11
    • Cancer Genomics and Diagnostics 6
    • MicroRNA in disease regulation 2
    • Breast Cancer Treatment Studies 2
Co-authors
Christina Yau (17 shared papers)A. Jo Chien (3 shared papers)Douglas Yee (11 shared papers)Rita Nanda (7 shared papers)Minetta C. Liu (5 shared papers)Laura Esserman (4 shared papers)Angela DeMichele (9 shared papers)Kathy S. Albain (2 shared papers)
Journals
Cancer Research (13 papers)Journal of Clinical Oncology (2 papers)Frontiers in Oncology (1 paper)BMC Medical Informatics and Decision Making (1 paper)npj Breast Cancer (1 paper)
Partner nations
United StatesAustraliaUnited Kingdom

In The Last Decade

Smita Asare

21 papers receiving 300 citations

Peers

Smita Asare
Comparison fields: 5 of 40
  • Transplantation 27
  • Oncology 183
  • Cancer Research 97
  • Immunology 75
  • Hepatology 21
Replace Nicolai Aagaard Schultz with:
Nicolai Aagaard Schultz Denmark
Jeroen Depreeuw Belgium
M Redon France
Cor H. van der Leest Netherlands
Timothy H.T. Cheng Hong Kong
Nikoletta Sidiropoulos United States
Benjamin Bonhomme France
Keitaro Shimozaki Japan
Lorenzo Ruggieri Italy
Smita Asare relative to Nicolai Aagaard Schultz Denmark Nicolai Aagaard Schultz's profile →
Citations per field
00.5×2×4×6×8×9×
Nicolai Aagaard Schultz · 1×
Citations per year

Countries citing papers authored by Smita Asare

Since Specialization
Citations

This map shows the geographic impact of Smita Asare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Smita Asare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Smita Asare more than expected).

Fields of papers citing papers by Smita Asare

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Smita Asare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Smita Asare. The network helps show where Smita Asare may publish in the future.

Co-authors

The 25 scholars most cited alongside Smita Asare, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Smita Asare Line = papers co-authored together Smita Asare links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.
Journal of Clinical Oncology ·Rita Nanda, Minetta C. Liu, Christina Yau, Smita Asare, Nola Hylton, Laura van’t Veer, Jane Perlmutter, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Anthony Elias, Donald A. Berry, Douglas Yee, Angela DeMichele, Laura Esserman
2017158
2
An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection
Hepatology ·Abraham Shaked, Bao‐Li Chang, Michael R. Barnes, Peter H. Sayre, Leslie A. Lange, Smita Asare, Michele Desmarais, Michael V. Holmes, Toumy Guettouche, Brendan J. Keating
201647
3
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
npj Breast Cancer ·Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Mark Jesus M. Magbanua, Nick O’Grady, Gillian L. Hirst, (unknown), Smita Asare, Debu Tripathy, Don Berry, Laura J. Esserman, A. Jo Chien, Emanuel F. Petricoin, Laura van ‘t Veer
202025
4
Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial
ICAN Infant Child & Adolescent Nutrition ·H. Peter Chase, Ellen Lescheck, Lisa Rafkin‐Mervis, Heidi Krause‐Steinrauf, Sonia Chritton, Smita Asare, Sara R. Adams, Jay S. Skyler, Michael Clare‐Salzler, (unknown)
200921
5
Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL
Cancer Research ·Michael J. Campbell, Christina Yau, Jennifer Bolen, Scott Vandenberg, Clifford Hoyt, Lamorna Brown Swigart, Gillian L. Hirst, Rita Nanda, Minetta C. Liu, Smita Asare, Laura van'tVeer, Douglas Yee, Angie DeMichele, Don Berry, Laura Esserman, (unknown)
201910
6
Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies
Cancer Research ·Christina Yau, DM Wolf, Michael J. Campbell, Peter Savas, Rose Lin, Lamorna Brown Swigart, Gillian L. Hirst, Smita Asare, Zelos Zhu, Sherene Loi, Angela DeMichele, Douglas Yee, Don Berry, Laura J. Esserman, Laura van ‘t Veer
20197
7
Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Cancer Research ·Christina Yau, Denise M. Wolf, Lamorna Brown Swigart, Gillian L. Hirst, Ashish Sanil, Ruby Singhrao, (unknown), Smita Asare, Angela DeMichele, Donald A. Berry, L. Esserman, Laura van ‘t Veer, Rita Nanda, Ming Liu, Douglas Yee
20186
8
Ancillary study management systems: a review of needs
BMC Medical Informatics and Decision Making ·Elizabeth Nelson, Britt Piehler, Adam Rauch, Sarah Ramsay, Drienna Holman, Smita Asare, Adam L. Asare, Mark Igra
20134
9
Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial
Cancer Research ·Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Emanuel F. Petricoin, Lamorna Brown Swigart, Gillian L. Hirst, Smita Asare, Douglas Yee, Angela DeMichele, Hope Rugo, Olufunmilayo I. Olopade, Rita Nanda, Minetta C. Liu, Laura Esserman, Laura van ‘t Veer
20193
10
Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial
Cancer Research ·Matthew T. Campbell, Christina Yau, Alexander D. Borowsky, Scott Vandenberg, DM Wolf, David L. Rimm, Rita Nanda, M Liu, Lamorna Brown Swigart, Gillian L. Hirst, Smita Asare, Laura van’t Veer, Dean Y. Yee, Angela DeMichele, Daniella R. A. I. Berry, Laura Esserman
20183
11
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
Frontiers in Oncology ·Katharine Yu, Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay, James E. Korkola, Gillian L. Hirst, Smita Asare, Angela DeMichele, Nola M. Hylton, Douglas Yee, Laura J. Esserman, Laura van ‘t Veer, Marina Sirota
20232
12
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL
Cancer Research ·Denise M. Wolf, Christina Yau, Michael J. Campbell, Hatem Soliman, Mark Jesus M. Magbanua, Ruixiao Lu, Nicholas O’Grady, Lamorna Brown Swigart, Gillian L. Hirst, Laura Sit, Yvonne M Florence, (unknown), Smita Asare, Douglas Yee, Angie DeMichele, Don Berry, Laura J. Esserman, Jo Chien, Laura van ‘t Veer
20222
13
Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer
Cancer Research ·A. Jo Chien, Kevin Kalinsky, Julissa Molina-Vega, Rita A. Mukhtar, Karthik V. Giridhar, Olufunmilayo I. Olopade, Amrita Basu, Smita Asare, Paul Henderson, Gillian L. Hirst, Ruixiao Lu, Ella F. Jones, Nola Hylton, Lamorna Brown Swigart, Laura van ‘t Veer, Douglas Yee, Ingrid Mayer, Laura J. Esserman
20222
14
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
JAMIA Open ·Nicholas O’Grady, David L. Gibbs, Kawther Abdilleh, Adam L. Asare, Smita Asare, Sara J. Venters, Lamorna Brown Swigart, Gillian L. Hirst, Denise M. Wolf, Christina Yau, Laura van ‘t Veer, Laura J. Esserman, Amrita Basu
20212
15
Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL.
Journal of Clinical Oncology ·W. Fraser Symmans, Christina Yau, Yunn‐Yi Chen, Brian Datnow, Shi Wei, Michael D. Feldman, Jon Ritter, Xiuzhen Duan, Beiyun Chen, Ronald Tickman, Husain Sattar, Anthony Magliocco, Bhaskar Kallakury, Megan L. Troxell, Smita Asare, Minetta C. Liu, Angela DeMichele, Douglas Yee, Donald A. Berry, Laura J. Esserman, (unknown)
20182
16
Abstract P1-21-08: Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial
Cancer Research ·Rosalyn W. Sayaman, Denise M. Wolf, Christina Yau, Julie Wulfkuhle, Emanuel F. Petricoin, Lamorna Brown Swigart, Smita Asare, Gillian L. Hirst, Laura Sit, Nicholas O’Grady, Diane Hedistian, Laura J. Esserman, Mark A. LaBarge, Laura van ‘t Veer
20201
17
Abstract PD14-02: Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer
Cancer Research ·Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Nick O’Grady, Gillian L. Hirst, Laura Sit, Smita Asare, Don Berry, Laura J. Esserman, Hyo S. Han, Lajos Pusztai, Laura van ‘t Veer
20211
18
Abstract GS5-04: Identification of symptoms that are associated with irAEs in the I-SPY clinical trial
Cancer Research ·Amrita Basu, Saumya Umashankar, Michelle Melisko, Ruixiao Lu, Hongmei Yu, Christina Yau, Smita Asare, Maria Pitsouni, Rebecca Shatsky, Claudine Isaacs, Angela DeMichele, Dawn L. Hershman, Rita Nanda, Mi‐Ok Kim, Laura J. Esserman, Hope Rugo
20231
19
Potential Application of Serum miRNA Signature for Minimization of Immunosuppression and Diagnosis of Rejection Following Liver Transplantation.
Transplantation ·Abraham Shaked, B. Chang, Toumy Guettouche, Smita Asare, Deborah Phippard, Michele Desmarais, Brendan J. Keating
20141
20
Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies
Cancer Research ·Hatem Soliman, Denise M. Wolf, Jo Chien, Christina Yau, M. Campbell, Mark Jesus M. Magbanua, Ruixiao Lu, Nicholas O’Grady, Lamorna Brown Swigart, Gillian L. Hirst, Beverly Parker, Laura Sit, Smita Asare, Douglas Yee, Angie DeMichele, Rita Nanda, Lajos Pusztai, Don Berry, Laura J. Esserman, Laura van’t Veer
20221

About Smita Asare

Smita Asare is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Surgery, having authored 22 papers that have together received 300 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers), Radiomics and Machine Learning in Medical Imaging (5 papers), MicroRNA in disease regulation (2 papers), Breast Cancer Treatment Studies (2 papers), Genetic factors in colorectal cancer (2 papers), Cancer Treatment and Pharmacology (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Transplantation (27 citations), Oncology (183 citations), Cancer Research (97 citations), Immunology (75 citations) and Hepatology (21 citations). Smita Asare has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Christina Yau, A. Jo Chien, Douglas Yee, Rita Nanda, Minetta C. Liu, Laura Esserman, Angela DeMichele, Kathy S. Albain, Laura van’t Veer and Erin D. Ellis. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Frontiers in Oncology, BMC Medical Informatics and Decision Making and npj Breast Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolai Aagaard SchultzBreakdown of academic impact, for papers by Jeroen DepreeuwBreakdown of academic impact, for papers by M RedonBreakdown of academic impact, for papers by Cor H. van der LeestBreakdown of academic impact, for papers by Timothy H.T. ChengBreakdown of academic impact, for papers by Nikoletta SidiropoulosBreakdown of academic impact, for papers by Benjamin BonhommeBreakdown of academic impact, for papers by Keitaro ShimozakiBreakdown of academic impact, for papers by Lorenzo Ruggieri